| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7341210a0e57c558ee665835a6985458 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-5412
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64 |
| filingDate |
2017-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a68f07406bb2f2315f33d457f684dc0 |
| publicationDate |
2018-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2018050808-A1 |
| titleOfInvention |
Antineoplastic fusion protein |
| abstract |
The invention relates to the field of therapeutic recombinant fusion proteins. Specifically, the invention relates to fusion proteins of Pseudomonas exotoxin A in combination with a human oncostatin M (OSM) fragment or a mutant form of an oncostatin M fragment, to a mutant form of an oncostatin M fragment, and to the use thereof in antineoplastic therapy. |
| priorityDate |
2016-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |